C-CAR168 cell therapy for progressive multiple sclerosis that standard treatment has not controlled
Tests C-CAR168, a CAR T-cell therapy, in adults with progressive multiple sclerosis.
Plain-language title generated from the registry record
Registry title: C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
Key facts
- Where
- Gilbert and La Jolla, United StatesSee the 2 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07825389, who can take part
Where in United States
- GilbertGilbert, United StatesNo longer taking part
- La JollaLa Jolla, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbelZeta Inc.
- Trial code
- NCT07825389
- Record updated
- 13 October 2026
- Original description
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).Read full original descriptionShow less
Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).
Inclusion: Able to sign and date the informed consent form; Male or female, 18-55 years of age, body weight >=40 kg; Diagnosis of MS according to the 2024 McDonald criteria with cohort-specific progressive MS requirements; Cohort 1: active SPMS; Cohort 2: PPMS or non-active SPMS; Inadequate response to at least one prior high-efficacy disease-modifying therapy administered for at least 6 months; Documented disability progression over the prior 24 months; EDSS 3.0 to 6.5, inclusive; Meets protocol-defined disease-duration, CSF, organ-function, cardiac/pulmonary, pregnancy testing, contraception, vaccination, and cellular-therapy follow-up requirements.
Exclusion: Inadequate washout from prior MS therapy or specified recent immunomodulatory treatments; Prior CAR T-cell therapy, other genetically modified immune cell therapy, or gene therapy; RRMS, clinically isolated syndrome, radiologically isolated syndrome, or another diagnosis better explaining the neurologic course; Alternative inflammatory demyelinating disorders, including AQP4-antibody-positive NMOSD and MOG-antibody-associated disease; Active or chronic infection requiring antibiotics, or protocol-specified positive infectious disease testing; Specified major cardiovascular, neurologic, transplant, malignancy, bleeding/thromboembolic, allergy, or protocol-compliance exclusions; Pregnant or breastfeeding, or planning pregnancy during the protocol-defined follow-up period.